Drug Safety | Pfizer

Pfizer’s Drug Safety R&D group develops and applies the skills, experience and scientific tools necessary for safety assessment and risk management of targets and compounds across the research, development and commercial phases of drug development. We seek to enhance our capabilities for target safety assessment, selection of safer compounds, toxicity risk management and translation of preclinical models.

We are interested in establishing alliances to develop and access:

Mechanisms, translatable and monitorable biomarkers, and screening approaches related to target organ toxicity
- Cardiovascular safety including vascular injury and early detection of cardiotoxicity
- CNS biomarkers including peripheral neuropathy
- Liver injury in particular immune-mediated DILI and transporters
- Immunostimulation, including hypersensitivity, autoimmunity, cytokine release
- Nephrotoxicity – glomerular and tubular
- Skeletal and cardiac muscle toxicity
- Pancreatic toxicity
- Ocular safety
- Screening for abuse potential
Animal models, biomarkers and screening approaches for preclinical immuno-oncology investigation, supporting mono- and combination-therapy approaches (interpretation and translatability)
- Immune system components and responses comparability between preclinical species and human
Biotherapeutics-related analytical technologies
- Immunogenicity and other safety-relevant assays
- Assays related to aggregation, subvisible particles
3D and complex models including stem cell approaches and microfluidics
Deeper knowledge of targets and pathways
- Knock-in, knock-out technologies
- Novel technologies and increased throughput for target localization studies
- Novel technologies and increased throughput for target localization studies
Safety biomarker technologies/enablers
- Emerging platforms, including miRNA-based multiplex; analytical approaches
- Academic collaborations to leverage annotated biofluid collections to understand target organ toxicities and enable clinical translation
Advancing Regulatory Science
- Systems pharmacology approaches for prediction of adverse events
- Novel in silico modelling approaches for pro-arrhythmia detection

Not actively seeking partnering opportunities in:

Genetox Screening
hERG related assays
In vitro screening models without significant validation